PSMA PET/MRI 在 PI-RADS 3 病变中的诊断价值:PANDORA 前瞻性配对研究
这项单中心前瞻性配对诊断研究纳入 66 例 PI-RADS 3 且具高危特征的可活检男性,比较 PSMA PET 靶向活检与 MRI 靶向活检对临床显著前列腺癌(csPCa)的检出率。PSMA PET 阴性者活检可避免 45/66(68%),且均无 csPCa。
要点
- PSMA PET 灵敏度 100%、特异度 82%、阴性预测值 100%。
- PSMA PET 阴性者 68% 可避免活检,且均无 csPCa。
核心结论
- 在 PI-RADS 3 可疑病变的可活检男性中,PSMA PET 靶向活检较 MRI 靶向活检检出更多 csPCa,且 PSMA PET 阴性预测值高,阴性后延迟活检值得在多中心大样本中评估。
研究设计与样本
- 入组为诊断 MRI 显示 PI-RADS 3 且至少 1 项高危特征的可活检男性,活检前接受 [18F]JK-PSMA-7 PSMA PET/MRI,阳性定义为 PRIMARY 评分 ≥ 3。
- 所有患者接受经会阴 MRI 靶向活检、PSMA PET 阳性时的 PSMA PET 靶向活检及系统活检。
主要发现
- PSMA PET 阳性 21/66(32%)。
- PSMA PET 灵敏度 100%、特异度 82%、阴性预测值 100%。
- PSMA PET 阴性者 45/66(68%)可避免活检,均无 csPCa。
关键数值与推荐
- csPCa 定义为国际泌尿病理学会分级分组 ≥ 2 且 Gleason 4 模式 ≥ 10%。
- PSMA PET 阳性定义为 PRIMARY 评分 ≥ 3。
- 主要结局为患者层面 csPCa 检出率,采用精确 McNemar 检验比较。
临床怎么用
- 对 PI-RADS 3 且具高危特征的可活检男性,可考虑活检前 PSMA PET/MRI 以指导靶向活检。
- PSMA PET 阴性(PRIMARY 评分 < 3)者 csPCa 风险低,或可延迟活检,但需进一步多中心验证。
局限性
- 单中心研究,样本量有限(66 例完成者)。
- 需更大规模多中心研究验证阴性后延迟活检策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Equivocal Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions carry an intermediate risk of clinically significant prostate cancer (csPCa). We evaluated the diagnostic value of prostate-specific membrane antigen positron emission tomography/MRI (PSMA PET/MRI) with [18F]JK-PSMA-7, performed after diagnostic MRI, in biopsy-eligible men with an equivocal PI-RADS category 3 lesion. We hypothesized that PSMA PET-targeted biopsy would detect more csPCa than MRI-targeted biopsy. MATERIALS AND METHODS: We conducted a single-center prospective paired diagnostic study from November 2023 to February 2026. Biopsy-eligible men with an equivocal PI-RADS category 3 lesion on diagnostic MRI and ≥ 1 high-risk feature underwent prebiopsy PSMA PET/MRI, with positivity defined as a PRIMARY score ≥ 3, followed by transperineal MRI-targeted, PSMA PET-targeted when positive, and systematic biopsy. The primary outcome was the per-patient csPCa detection rate (International Society of Urological Pathology grade group ≥ 2 with ≥ 10% Gleason pattern 4) of PSMA PET-targeted vs MRI-targeted biopsy, assessed with the exact McNemar test. RESULTS: Of 83 men assessed, 66 completed PSMA PET/MRI and biopsy. PSMA PET was positive in 21 of 66 (32%). PSMA PET-targeted biopsy detected csPCa in 10 of 66 (15%) vs 4 of 66 (6%) for MRI-targeted biopsy (difference 9%; 95% CI 2%-18%; P = .03). Sensitivity, specificity, and negative predictive value of PSMA PET were 100%, 82%, and 100%, respectively. Biopsy would have been avoided in 45 of 66 men (68%) with a negative result, none of whom had csPCa. CONCLUSIONS: In biopsy-eligible men with an equivocal PI-RADS category 3 lesion, PSMA PET-targeted biopsy detected more csPCa than MRI-targeted biopsy. The high negative predictive value suggests that deferral of biopsy after a negative result merits evaluation in larger multicenter studies.
引用
- Diamand R, Artigas C, Peltier A, et al. Diagnostic Value of Prostate-Specific Membrane Antigen Positron Emission Tomography/MRI in Selected Men With Equivocal Prostate Imaging Reporting and Data System Category 3 Lesion (PANDORA): A Prospective Paired Diagnostic Study. J Urol. 2026. PMID: 42849042. doi:10.1097/JU.0000000000005343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。